Alpha Galactosidase(Fabry)

The Alpha Galactosidase(Fabry) test measures the activity of alpha-galactosidase A, an enzyme responsible for breaking down certain fatty substances within the body's cells. Reduced or absent activity of this enzyme is associated with Fabry disease, a rare inherited lysosomal storage disorder caused by changes in the GLA gene. When the enzyme does not work properly, substances such as globotriaosylceramide can accumulate in cells and gradually affect the kidneys, heart, nervous system, skin, eyes and other organs. Testing can support early detection, timely specialist assessment and appropriate management.

Benefits of the Test

• Measures alpha-galactosidase A enzyme activity.
• Helps identify males who may have Fabry disease.
• Supports investigation of unexplained Fabry-related symptoms.
• May be used to screen relatives of a person with a confirmed diagnosis.
• Helps guide genetic testing, specialist consultation and further clinical evaluation.
• Supports earlier recognition before significant organ damage develops.

Why Doctors Recommend This Test

A doctor may recommend this test when a person has symptoms or a family history suggestive of Fabry disease. Possible features include burning pain or tingling in the hands and feet, reduced ability to sweat, difficulty tolerating heat or exercise, clusters of small dark-red skin spots called angiokeratomas, gastrointestinal discomfort, corneal changes, hearing problems, unexplained kidney dysfunction, thickening of the heart muscle or stroke at a relatively young age. The clinical presentation varies considerably, so enzyme results must be evaluated with the patient's symptoms, sex, family history and other investigations.

Low alpha-galactosidase A activity strongly supports Fabry disease in many affected males. However, females with a GLA gene variant can have enzyme activity within the normal range because Fabry disease is X-linked and enzyme production may vary between cells. Therefore, a normal enzyme result does not reliably exclude Fabry disease in females. Molecular testing of the GLA gene is commonly required to confirm the diagnosis and may also be recommended for males after an abnormal enzyme result.

Preparation Before Test

No fasting is generally required unless the doctor or laboratory provides specific instructions. Tell the healthcare team about current medicines, supplements, previous enzyme-replacement treatment and any known family history of Fabry disease. The required sample may be blood, leukocytes or a dried blood spot depending on the testing method. Follow the collection instructions carefully because correct sample handling is important for reliable enzyme measurement.

Normal Reporting Time

This is a specialized enzyme assay and results are generally available within several working days. Reporting time may vary according to the sample type, laboratory schedule, transport requirements and whether repeat analysis or confirmatory testing is necessary. Focus Diagnostics will provide the applicable turnaround estimate when the sample is collected.

Who Should Take This Test?

• People with symptoms clinically suggestive of Fabry disease.
• Individuals with unexplained kidney, cardiac or neurological abnormalities.
• Male relatives of a person with confirmed Fabry disease or a known GLA variant.
• People referred after an abnormal newborn or family screening result.
• Patients advised to undergo enzyme testing by a geneticist, neurologist, nephrologist, cardiologist or other specialist.

Detailed Information

Fabry disease is inherited in an X-linked pattern. Affected males frequently have markedly reduced enzyme activity, while females may show a broad range of activity and symptoms. The test result should not be interpreted as a stand-alone diagnosis. An abnormally low value is usually followed by clinical assessment and GLA gene analysis. Additional examinations may include kidney-function testing, urine protein measurement, cardiac imaging, electrocardiography, neurological assessment, hearing evaluation and measurement of relevant disease biomarkers.

Finding Fabry disease early is important because organ involvement can progress over time. Depending on the confirmed diagnosis and individual clinical findings, management may include regular monitoring, symptom control, enzyme-replacement therapy, pharmacological chaperone therapy for eligible gene variants and family counselling. A genetic counsellor can explain inheritance, testing options for relatives and reproductive considerations. Always discuss the result with the referring doctor, who can interpret it using the laboratory's reference interval and the complete clinical picture.